NUCLEA BIOTECHNOLOGIES, INC.
|NUCLEA BIOTECHNOLOGIES, INC. Patent applications|
|Patent application number||Title||Published|
|20130237691||USP2A PEPTIDES AND ANTIBODIES - The invention relates to novel USP2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment.||09-12-2013|
|20130237449||USP2A PEPTIDES AND ANTIBODIES - The invention relates to novel USP2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment.||09-12-2013|
|20130095483||PREDICTIVE BIOMARKERS FOR BREAST CANCER - The invention relates to compositions and methods for detecting, screening, diagnosing or determining the progression of, regression of and/or survival from a proliferative disease or condition, specifically breast cancer. The invention also provides new assays and kits for the staging or stratifying breast cancer patients or patients suspected of having breast cancer.||04-18-2013|
|20120165218||METHOD AND ASSAY FOR DETERMINING FAS EXPRESSION - Methods and immunoassays for the determination of fatty acid synthase (FAS) expression in patients having or suspected of having a proliferative disorder, especially prostate cancer, are disclosed. The sensitive method and assay detect the level of expression of FAS in a biological sample using antibodies that are highly specific for FAS. The method and assay can be used to monitor the progression of cancer, and/or to predict the efficacy of certain treatments or the likelihood of recurrence of the cancer.||06-28-2012|
|20120149594||BIOMARKERS FOR PREDICTION OF BREAST CANCER - The invention provides gene expression profiles (GEPs), protein expression profiles (PEPs) as well as gene/protein expression profiles (GPEPs) and methods for using them to identify those patients who are likely to progress to breast cancer after detection of suspicious calcifications and/or fibrocystic disease by standard imaging techniques, e.g., mammography, MRI or ultrasound. The present invention further allows a treatment provider to identify those patients who are most likely to develop breast cancer to initiate and/or adjust treatment options for such patients accordingly.||06-14-2012|
|20120020978||ANTIBODIES AGAINST FATTY ACID SYNTHASE - The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.||01-26-2012|
Patent applications by NUCLEA BIOTECHNOLOGIES, INC.